Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» elafibranor
elafibranor
GenFit Moves Lead Candidate into Another Phase III Trial with Breakthrough Therapy
GenFit Moves Lead Candidate into Another Phase III Trial with Breakthrough Therapy
BioSpace
Genfit
breakthrough therapy
FDA
primary biliary cholangitis
elafibranor
Flag link:
Genfit bags FDA breakthrough tag on route to phase 3 in PBC
Genfit bags FDA breakthrough tag on route to phase 3 in PBC
Fierce Biotech
Genfit
FDA
primary biliary cholangitis
elafibranor
clinical trials
Flag link:
The 20 Hottest Pipeline Drugs to Watch in 2019
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor
Flag link:
While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients
While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients
Endpoints
Genfit
NASH
Gilead Sciences
Intercept Pharma
clinical trials
elafibranor
Flag link:
GENFIT Receives Positive Safety Review for NASH Candidate Elafibranor
GENFIT Receives Positive Safety Review for NASH Candidate Elafibranor
CP Wire
Genfit
NASH
elafibranor
Flag link:
Genfit launches a PhIII study for NASH drug
Genfit launches a PhIII study for NASH drug
Fierce Biotech
Genmit
NASH
elafibranor
clinical trials
Flag link:
